Physician profile
Ann S Chu
NPI 1982788519
$549.24
in general payments reported to CMS, 2019-2025
18 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $73.59 · 2021: $29.50 · 2024: $113 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $57.28 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $55.26 | 2019-2025 | Ozempic |
| Abbvie INC. | $55.13 | 2024 | |
| Lilly USA, LLC | $48.63 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $45.75 | 2019-2020 | |
| Dexcom, INC. | $38.89 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $34.14 | 2019-2020 | |
| Allergan, INC. | $29.84 | 2019 | |
| Boston Scientific Corporation | $29.50 | 2021 | |
| Beta Bionics, INC. | $22.93 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Glaxosmithkline, LLC. | $22.11 | 2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $20.58 | 2025 | Airsupra |
| Amgen INC. | $18.40 | 2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $16.09 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $14.21 | 2020 | |
| Strongbridge US INC. | $11.96 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.